91 results about "Lymphatic metastasis" patented technology

The present invention relates to a neuropilin-1 ligand polypeptide-polyethylene glycol-phospholipid composite, its active targeting liposome vector system and a preparation method thereof. The liposome vector system comprises the following components: a: phospholipid, b: cholesterol, c: methoxy polyethylene glycol-phospholipid composite (with the molecular weight of methoxy polyethylene glycol ranging from 400 to 6000), and d: a RPAKPAR sequence-containing polypeptide-polyethylene glycol-phospholipid composite (with the molecular weight of polyethylene glycol ranging from 400 to 8000). And for the components, a and b are in a molar ratio of 5:1-1:5, a and c are in a molar ratio of 1000:1-1000:100, and a and d are in a ratio of 1000:0.1-1000:100. The system can make a liposome passively drained into a lymphatic system through subcutaneous interstitial injection or intramuscular injection, and can make the liposome targeted to a lymphatic metastasis lesion through the mediation effect of RPAKPAR. The system can also make the liposome targeted to a primary tumor and a hematogenous metastasis lesion directly through intravenous injection administration, through a tumor EPR (electron paramagnetic resonance) effect and the mediation effect of RPAKPAR. The liposome vector system of the invention can be used for targeted drug delivery in diagnosis or treatment of prostate cancer primary tumors and metastatic tumors.

The invention belongs to the field of pharmaceutical chemistry, relating to a folic acid-polyethyleneglycol composite which can be combined with imageology nuclide for tumor diagnosis, wherein the folic acid composite folic acid, the polyethyleneglycol, functional oligomerized polylysine and a plurality of DTPA are connected in a covalent bond mode. After applying the folic acid composite to animal nuclear magnetic resonance or radioactive video picture diagnosis, experiment results show that the type of the composite is lead to lymphatic system without transmitting blood capillaries at tissue spaces, is dynamically concentrated and eliminated at lymph glands, combines with high-expressive tumor cells of folate receptors in a competitiveness mode, and presents excellent lymph guiding property and accumulative property of tumor locations. The invention can be effectively used for target diagnosis of tumors and metastatic tumors of the lymphatic system, and has high targeting property and high resolution of the tumor and lymphoma diagnosis.

The invention discloses an application of EB virus encoded microRNA BART10 (EBV-miR-BART10) in preparing a prediction preparation for recurrence and metastasis of nasopharyngeal carcinoma. The research proves that the expression level of EBV-miR-BART10 in the nasopharyngeal carcinoma tissue is in positive correlation with the lymphatic metastasis and the distant metastasis of the nasopharyngeal carcinoma patient; if the expression of the EBV-miR-BART10 in the nasopharyngeal carcinoma tissue is up-regulated, the nasopharyngeal carcinoma patient with higher EBV-miR-BART10 expression have larger possibilities of recurrence and metastasis than the nasopharyngeal carcinoma patient with lower EBV-miR-BART10 expression, and the prognosis is worse, therefore, the application of the expression of the EBV-miR-BART10 in the predication of recurrence and metastasis of the nasopharyngeal carcinoma patient can provide powerful biomolecular basis for the prognosis of the nasopharyngeal carcinoma patient, and thus the application method has profound clinical significances and important popularization and application prospects.

The invention relates to an optimum mass spectrometry model and a preparation method thereof for detecting the feature protein of nasopharyngeal cancer, belonging to the field of mass spectrometry detection technique. The invention is characterized in that six up-regulated proteins and five lower-regulated proteins are screened from the blood serum to be used as the feature proteins; any two or more proteins of the eleven proteins are chosen so as to establish a blood serum feature protein mass spectrometry model of identification with two in a group for patients with nasopharyngeal cancer and normal people, and patients with benign nasopharyngeal cancer disease, lymphatic metastasis of nasopharyngeal cancer and remote metastasis of nasopharyngeal cancer according to the mass-charge ratio m / z of each protein peak and the critical peak average value of the protein; the preparation method of the invention provides a foundation for discovering new nasopharyngeal cancer biological marks. The method of the invention is better than any single detection method adopted currently for the detection of the nasopharyngeal cancer, and provides a non-invasive technique for the early detection and early treatment of the nasopharyngeal cancer, thus providing a new method for reducing the mortality of the nasopharyngeal cancer, improving the cure rate of the nasopharyngeal cancer and screening and examining the nasopharyngeal cancer for high-risk population further.

The invention relates to an optimum mass spectrometry model and a preparation method thereof for detecting the feature protein of renal cancer, belonging to the field of mass spectrometry detection technique. The invention is characterized in that seven up-regulated proteins and three lower-regulated proteins are screened from the blood serum to be used as the feature proteins; any two or more proteins of the ten proteins are chosen so as to establish a blood serum feature protein mass spectrometry model of identification with two in a group for patients with renal cancer and normal people, and patients with benign renal cancer disease, lymphatic metastasis of renal cancer and remote metastasis of renal cancer according to the mass-charge ratio m / z of each protein peak and the critical peak average value of the protein; the preparation method of the invention provides a foundation for discovering new renal cancer biological marks. The method of the invention is better than any single detection method adopted currently for the detection of the renal cancer, and provides a non-invasive technique for the early detection and early treatment of the renal cancer, thus providing a new method for reducing the mortality of the renal cancer, improving the cure rate of the renal cancer and screening and examining the renal cancer for high-risk population further.

The invention relates to a grading model for detecting lymphoma and lymphatic metastatic cancer and application of the grading model. According to the model, change of imprinting genes in lymphoma andlymphatic metastatic cancer is graded by calculating imprinting gene deletion expression quantity, imprinting gene copy number abnormal expression quantity and imprinting gene total expression quantity. The expression of imprint deletion on tissues and cell samples of lymphoma and cancer lymphatic metastasis patients is represented by an intuitive method; through an imprinting gene in-situ labeling method, the change of imprinting genes can be objectively, visually, early and accurately detected, the quantitative model can be provided, and great contribution is made to diagnosis of lymphoma and lymphatic metastatic cancer.

The invention relates to hydrogel nanoparticles used as an injectable subcutaneous implant agent, which can effectively solves the problem of fulfilling an aim of realizing tumor treatment by locally injecting the hydrogel nanoparticles beside a subcutaneous tumor, changing the hydrogel nanoparticles into a gel and slowly releasing nanoparticles in vivo. The hydrogel nanoparticles are prepared from hydrogel solution and 2-methoxyl estradiol liposome nanoparticle powder or solid liposome nanoparticle powder by a method which comprises the following steps of: adding the 2-methoxyl estradiol liposome nanoparticle powder or the solid liposome nanoparticle powder into the hydrogel solution; and uniformly mixing to form the hydrogel nanoparticles which can be used as an injectable subcutaneous implant agent, wherein 100mg of the 2-methoxyl estradiol liposome nanoparticle powder is added into every 1ml of the hydrogel solution. The injectable hydrogel implant agent of the invention can be used for treating subcutaneous tumors such as breast cancer and the like, keep an effective medicament concentration in a local target site, can realize sustained release and controlled release, can avoid medicament resistance caused by long-term medication, simultaneously improve a curative effect and reduce dosage, reduce toxic and side effects on a whole body, and also can prevent lymphatic metastasis of the tumors such as the breast cancer and the like.